Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Ejemplares similares

• Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)
  por: Clement, P. M., et al.
  Publicado: (2016)
• Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
  por: Burtness, Barbara, et al.
  Publicado: (2014)
• Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
  por: Guo, Y, et al.
  Publicado: (2019)
• Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
  por: Cohen, E. E. W., et al.
  Publicado: (2017)
• Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
  por: Young, Natalie R., et al.
  Publicado: (2015)